QUANTRX BIOMEDICAL CORPORATION: 10-Q filed 2022-11-14
What QUANTRX BIOMEDICAL CORPORATION reported in its quarterly report filed 2022-11-14 (fiscal Q3 2022): 20 published measures, 57 facts as tagged in accession 0001493152-22-031830.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-11-14
- Fiscal period
- fiscal Q3 2022
- Accession
- 0001493152-22-031830 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All QUANTRX BIOMEDICAL CORPORATION filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 5,383 | USD | |
| At 2021-12-31 | 5,950 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 2,845,948 | USD | |
| At 2021-12-31 | 2,647,047 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | -2,840,565 | USD | |
| At 2022-06-30 | -2,779,399 | USD | |
| At 2021-12-31 | -2,641,097 | USD | |
| At 2021-09-30 | -2,580,058 | USD | |
| At 2021-06-30 | -2,517,043 | USD | |
| At 2020-12-31 | -2,381,055 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 3,884 | USD | |
| At 2021-12-31 | 5,950 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -61,166 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -199,468 | USD | 273 |
| 2021-07-01 to 2021-09-30 | -63,015 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -199,003 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | -33,066 | USD | 273 |
| 2021-01-01 to 2021-09-30 | -34,377 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 31,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | -52,574,496 | USD | |
| At 2021-12-31 | -52,375,028 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 78,696,461 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 78,696,461 | shares | 273 |
| 2021-07-01 to 2021-09-30 | 78,696,461 | shares | 92 |
| 2021-01-01 to 2021-09-30 | 78,696,461 | shares | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 0 | USD | 273 |
| 2021-01-01 to 2021-09-30 | 0 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -7,250 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -37,756 | USD | 273 |
| 2021-07-01 to 2021-09-30 | -8,542 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -36,820 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 5,383 | USD | |
| At 2021-12-31 | 5,950 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 53,916 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 161,712 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 54,473 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 162,183 | USD | 273 |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 16,475 | USD | |
| At 2021-12-31 | 10,219 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 2,903 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 9,514 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 2,810 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 9,457 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 78,696,461 | shares | |
| At 2021-12-31 | 78,696,461 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 48,876,398 | USD | |
| At 2021-12-31 | 48,876,398 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -61,166 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -199,468 | USD | 273 |
| 2021-07-01 to 2021-09-30 | -63,015 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -199,003 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -53,916 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -161,712 | USD | 273 |
| 2021-07-01 to 2021-09-30 | -54,473 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -162,183 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 6,256 | USD | 273 |
| 2021-01-01 to 2021-09-30 | 2,442 | USD | 273 |
Inspect the source
- Entity
- QUANTRX BIOMEDICAL CORPORATION / CIK 0000820608
- Captured
- SEC response SHA-256
9ed677f1f65a020d7443764a5b8258c716645c1ae82e75ef1907f7558ecaa289
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000820608.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))